Review: Atypical antipsychotic drugs increase risk for death in dementia

March 2006
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p36
Academic Journal
This article presents a study which reveals that atypical antipsychotic drugs increase risk for death in dementia. 5 placebo controlled trials (RCT) with 16 comparisons met the selection criteria. 9 RCTs were unpublished. 87% of patients had Alzheimer disease. Patients were nursing home residents in 11 RCTs and outpatients in 4 RCTs. Median duration of treatment was 10 weeks. The drugs studied included aripiprazole, olanzapine, risperidone, and quetiapine. About one third of patients in both intervention and placebo groups dropped out before completion.


Related Articles

  • Ginkgo biloba has no effect on dementia progression.  // Australian Journal of Pharmacy;Aug2009, Vol. 90 Issue 1071, p70 

    The article reports that Ginkgo biloba (G biloba) has no effect on dementia progression. It mentions that in a conducted study, 523 people had developed dementia, 246 receiving placebo and 277 receiving G biloba, in which 92% of the volunteers have been classified as possible or probable...

  • Ginkgo biloba for dementia. Stevermer, James J.; Lindbloom, Erik J. // Journal of Family Practice;Jan1998, Vol. 46 Issue 1, p20 

    The article presents a study, which assessed the safety and efficacy of Ginkgo biloba or EGb 761 in patients with dementia. Ginkgo biloba is used in Europe to alleviate symptoms from chronic neurological diseases. It is one of the most commonly prescribed medications in Germany. Three hundred...

  • Review: atypical antipsychotics may be useful in treating behavioural and psychological symptoms of dementia but cause adverse effects. Tariot, Pierre N. // Evidence Based Mental Health;Feb2005, Vol. 8 Issue 1, p16 

    The article presents a study on the effectiveness of atypical antipsychotics in treating behavioral and psychological symptoms of dementia. Researchers observed that at 6-12 weeks, both risperidone and olanzapine significantly reduced scores for BPSD compared with placebo in four trials. Limited...

  • ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia. Jeste, Dilip V.; Blazer, Dan; Casey, Daniel; Meeks, Thomas; Salzman, Carl; Schneider, Lon; Tariot, Pierre; Yaffe, Kristine // Neuropsychopharmacology;May2008, Vol. 33 Issue 6, p957 

    In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). The largest number of antipsychotic prescriptions in older adults is for behavioral...

  • The effects of a comprehensive rehabilitation program of Alzheimer's Disease in a hospital setting. Raggi, Alberto; Iannaccone, Sandro; Marcone, Alessandra; Ginex, Valeria; Ortelli, Paola; Nonis, Alessandro; Giusti, Maria Cristina; Cappa, Stefano F. // Behavioural Neurology;2007, Vol. 18 Issue 1, p1 

    Introduction. The evidence for the clinical effectiveness of cognitive rehabilitation in patients with Alzheimer's Disease (AD) is debated. Therefore it is important to collect more evidence about the outcome of non-pharmacological therapy of dementia. Material and Methods. We report data...

  • News in brief ...  // PharmacoEconomics & Outcomes News;7/16/2005, Issue 482, p8 

    Presents the results of a study regarding the link between the use of antipsychotics or concomitant use of psychotropics with an increased mortality rate in elderly patients with dementia. Reference to a study by S. Hartikainen et al published in a July 2005 issue of "International Clinical...

  • Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Gentile, Salvatore // Psychopharmacology;Oct2010, Vol. 212 Issue 2, p119 

    Rationale: Antipsychotic drugs are widely used as a first-line pharmacological approach to treat dementia-related psychiatric symptoms. However, in this population of patients, such drugs have been associated with severe safety concerns. Hence, the aim of this review is to asses systematically...

  • Severe agitation in severe early-onset Alzheimer's disease resolves with ECT. Aksay, Suna Su; Hausner, Lucrezia; Frölich, Lutz; Sartorius, Alexander // Neuropsychiatric Disease & Treatment;2014, Vol. 10, p2147 

    Dementia-related behavioral disturbances are mostly treated with antipsychotics; however, the observed beneficial effects are modest and the risk of serious adverse effects high. We report the case of a 57-year-old woman with severe early-onset Alzheimer's disease and severe agitation, whom we...

  • A comparison of unawareness in frontotemporal dementia and Alzheimer's disease. Salmon, E.; Perani, D.; Collette, F.; Feyers, D.; Kalbe, E.; Holthoff, V.; Sorbi, S.; Herholz, K. // Journal of Neurology, Neurosurgery & Psychiatry;Feb2008, Vol. 79 Issue 2, p176 

    Background: Loss of insight is a core diagnostic feature of frontotemporal dementia (FTD) and anosognosia is frequently reported in Alzheimer's disease (AD). Aim: To compare unawareness (anosognosia) for different symptoms, measured with a discrepancy score between patient's and caregiver's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics